About
Aperture Bio is a Boston (Allston, MA) biotech spun out of Massachusetts General Hospital in 2022, offering a single-cell proteomics platform with a predictive analytics layer that helps oncology drug developers make better preclinical decisions.
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Aperture Bio
Aperture Bio is a Boston (Allston, MA) biotech spun out of Massachusetts General Hospital in 2022, offering a single-cell proteomics platform with a predictive analytics layer that helps oncology drug developers make better preclinical decisions.
—
United States
BusinessLatest roundTotal raisedDate- Escalante
Drug discovery and diagnostics platform combining AI with single-molecule proteomics
$7M
$7M - Pepper Bio
Analyzes multi-layer biological data (including DNA, RNA, proteomic and phosphoproteomic data) to discover new drugs
Seed · $7M · 2023-12
$7M - Iambic Therapeutics
Uses AI to predict protein-ligand structures and generate molecular designs to discover new drugs
IPO · $462M · 2026-09
$462M
China
BusinessLatest roundTotal raisedDate- 元示科技
AI Virtual Cell (AIVC): a raw biological data engine and general-purpose cell foundation model forming a life sciences base, with an ultra-high-throughput cell perturbation platform to predict drug perturbation effects across cell types, for early-stage drug discovery at pharmaceutical companies and research institutions.
Angel · 2026-10
— - ATLATL Innovation Center
ATLATL is a life-science innovation and shared-lab operator founded in 2017 in Shanghai's Zhangjiang, providing move-in-ready labs, on-site CRO services and R&D platforms (gene and cell therapy, AI-assisted drug screening, large-molecule research) to early-stage biotech companies across Shanghai, Beijing, Shenzhen, Hong Kong, Singapore and Australia.
— - Phil Rivers Technology
Computational medicine and life world models using AI and high-performance computing to simulate disease mechanisms and drug efficacy, systematically discover new oncology targets, assess indications and predict responding patients for novel drug R&D
Series A2 · 2026-08
—
Europe
BusinessLatest roundTotal raisedDate- Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B - OutSee
AI analysis of individual genomes to predict disease biology and help drug developers find new targets
Seed · $2M · 2025-06
$2M - Rivercell
In-house automated wet lab generating large-scale single-cell perturbation data to train "AI virtual cell" models that predict human cell responses to drugs and genetic changes
Seed · 2026-10
—
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.